Thank you for your interest in enrolling in one of our studies.
New patients interested in participating in a clinical trial and in enrolling to possibly receive the newest, most advanced treatment for their vitreoretinal conditions, with the care and attention from our professional clinical trial staff.
New patients interested in enrolling a study, please click on the Enroll in this Study to send us an email. Include your name, the reason of your interest in this study and the office location you receive treatment. You will receive a reply from us within 48 - 72 hours.
The following studies are currently available for enrollment.
A PHASE IIIB/IV, Multicenter, Open-label, Single-arm study to investigate Faricimab (RO6867461) Treatment response in treatment-naïve, Underpresented patients with Diabetic Macular Edema.
A Randomized, Masked, Controlled Study of and Intravitreal ILUVIEN implant as baseline therapy in patients with Early Diabetic Macular Edema.
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.
A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in Subjects with wet Age-related Macular Degeneration (wAMD).
A Phase 2/3 Pivotal, Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema.
A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy.
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA
The Evaluation of the Agreement and Precision of the Notal Vision Home OCT in the Automatic Fluid Quantification in Patients with NV-AMD
A study to test the different doses of BI 764524 in patients who have had laser treatment for a type of diabetic eye disease called Diabetic Retinopathy with Diabetic Macula Ischemia
A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multicenter, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal
Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)
Randomized, Double masked Phase 3 study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal Aflibercept in participants with visual impairment secondary to TREATMENT-NAÏVE Diabetic Macular Edema.
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multicenter, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]
OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
A Phase II, Multicenter, Randomized, Double Masked, Active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with Diabetic Macular Edema.
A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in Subjects with wet Age-related Macular Degeneration (wAMD).
Protocol: ONL1204-RRD-002
A Phase 2, Randomized, Sham-Controlled, Single-Masked, Dose-Ranging, Multi-Center Study to Assess the Safety and Efficacy of Intravitreal ONL1204 in Subjects with Macula-off Rhegmatogenous Detachment.
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening.
Vitreous Proteomics in Eyes with a Macular Hole.
Randomized Trial Comparing Immediate versus Deferred Surgery for Symptomatic Epiretinal Membranes.
Central Florida and North Florida Patients
A 96-week, two arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy.
The purpose of this study is to evaluate the efficacy and safety of brolucizumab compared to PRP in subjects with PDR.
Central Florida and North Florida Patients
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration.
Central Florida and North Florida Patients
A phase 2, randomized, double masked, 4-armed, Sham controlled study of the efficacy, safety, and tolerability of ANX007 administered by intravitreal injections in patients with Geographic Atrophy secondary to age-related macular degeneration.
Central Florida and North Florida Patients
To evaluate subjects with for Geographic Atrophy Secondary to Age-Related Macular Degeneration by sequencing selected genes associated with AMD. Subjects who meet eligibility criteria will have the option to participate in ongoing or future Gyroscope Therapeutic sponsored studies.
For more information about clinical trials or if you should have any questions, please feel free to contact us.
Clermont
Daytona Beach
Kissimmee
Lady Lake
Lake Mary
Mount Dora
Orange City
Orlando
Palm Coast
Titusville
Fernandina Beach
Fleming Island
Jacksonville Oak Street
Jacksonville Perimeter Park
Lake City
Palatka
St. Augustine
Mondays - Fridays: 8AM to 5PM
Saturdays - Sundays: Closed
In Case of Emergency: 911
contact@floridaretinainstitute.com